1. Abian O, Alfonso P, Velazquez-Campoy A, Giraldo P, Pocovi M, Sancho J. Therapeutic strategies for Gaucher disease: miglustat (NB-DNJ) as a pharmacological chaperone for glucocerebrosidase and the different thermostability of velaglucerase alfa and imiglucerase. Mol Pharm. 2011;8(6):2390–7. doi: 10.1021/mp200313e .
2. Alonzi DS, Kukushkin NV, Allman SA, Hakki Z, Williams SJ, Pierce L, et al. Glycoprotein misfolding in the endoplasmic reticulum: identification of released oligosaccharides reveals a second ER-associated degradation pathway for Golgi-retrieved proteins. Cell Mol Life Sci. 2013. doi: 10.1007/s00018-013-1304-6 .
3. Ando S, Yu RK. Isolation and characterization of a novel trisialoganglioside, GT1a, from human brain. J Biol Chem. 1977;252(18):6247–50.
4. Arumugham RG, Tanzer ML. Abnormal glycosylation of human cellular fibronectin in the presence of swainsonine. J Biol Chem. 1983;258(19):11883–9.
5. Baek RC, Kasperzyk JL, Platt FM, Seyfried TN. N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice. Neurochem Int. 2008;52(6):1125–33. doi: 10.1016/j.neuint.2007.12.001 . S0197-0186(07)00329-4. [pii].